Amin, Nadia Laila <br/><br/>
QUESTION 1: Should we be using bisphosphonates for osteonecrosis complicating childhood acute lymphoblastic leukaemia?  [electronic resource] 

 -  Archives of disease in childhood  Mar 2016 
 - 287-90 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1468-2044 
<br/><br/><label>Standard No.: </label>10.1136/archdischild-2015-309934  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Alendronate--adverse effects<br/>Antineoplastic Agents--therapeutic use<br/>Bone Density Conservation Agents--adverse effects<br/>Diphosphonates--adverse effects<br/>Female<br/>Humans<br/>Osteonecrosis--chemically induced<br/>Pain--drug therapy<br/>Pamidronate<br/>Precursor Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Risedronic Acid--adverse effects